Vodis Pharmaceuticals Inc. (CSE:VP, FSE:1JV1, OTC:VDQSF) (“Vodis” or the “Company”) is pleased to report that it has been issued both a Standard Cultivation and Standard Processing Licence from Health Canada at its 12,000 sqft indoor facility in Delta, British Columbia.
The Company is immediately commencing its licensed operation with its acquired well-established and proven, proprietary live cultivars. In addition, we have accumulated an extensive seed collection that will serve as the foundation for future offerings and breeding. Jump-starting with proven, live mother plants significantly shortens the time horizon to bring unique cultivars to the Canadian craft cannabis market.
Further, the company is currently exploring co-packaging options to further accelerate its time to market and revenue.
We wish to thank our many loyal shareholders and supporters who have stood by the company in the past and presently, and look forward to rewarding that faith as we enter a new phase of the cannabis market and a new era for Vodis.
Our mission will be to provide the Canadian cannabis consumers with the best cannabis grown by small craft producers which we believe will be the growth area of the Canadian cannabis industry.
For further information please contact:
Mark Lotz, Chief Executive Officer and CFO
Vodis Pharmaceuticals Inc.
Dr. Earl Oliver
Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws including statements relating to the outlook of the business of the Company, the planned expenditures for upgrades and other renovations at the Company’s facilities in Delta, BC. Although the Company believes considering the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them as the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements, depending on, among other things, the risks that the private placement financings may not close for any reason (including the failure to obtain the required approvals or clearances from regulatory authorities) or that the terms of the private placement financing may differ from those that currently are contemplated. The statements in this news release are made as of the date of this release. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.